January 2008
59
354.2545). [a]D24 ꢁ14.2 (cꢀ1.0, CHCl3).
1.67—1.83 (2H, m), 2.35 (3H, s), 4.17 (1H, q, Jꢀ7.5 Hz), 4.82 (1H, d,
Jꢀ7.5 Hz), 6.98—7.01 (2H, m), 7.10 (2H, d, Jꢀ8.6 Hz), 7.13—7.17 (3H,
m), 7.52 (2H, d, Jꢀ8.6 Hz). 13C-NMR (CDCl3) d: 10.5, 21.6, 30.7, 59.9,
126.6, 127.1, 127.4, 128.5, 129.4, 137.5, 140.7, 143.1. MS (FAB) m/z 290
(Mꢂ1). The enantiomeric excesses of 3a obtained by chiral ligands 5 and 6
were determined before recrystallization. HPLC condition: Daicel Chiralcel
OD, hexane/iPrOHꢀ10/1, 0.7 ml/min, 254 nm, minor 14.1 min and major
15.9 min.
References
1) Herrrmann W. A., Kocher C., Angew. Chem. Int. Ed. Engl., 36, 2162—
2187 (1997).
2) Bourrissou D., Guerret O., Gabbai F. P., Bertrand G., Chem. Rev., 100,
39—91 (2000).
3) Arduengo III, A. J., Harlow R. L., Kline M. A., J. Am. Chem. Soc.,
113, 361—363 (1991).
4) Hillier A. C., Grasa G. A., Viciu M. S., Lee H. M., Yang C., Nolan S.
P., J. Organomet. Chem., 653, 69—82 (2002).
N-[1-(4-Chlorophenyl)propyl]-4-methylbenzenesulfonamide32) (3b): Col-
orless needles (recrystallized from n-hexane/CH2Cl2), 136—139 °C; IR
(ATR) cmꢁ1 3244, 1317, 1165. 1H-NMR (CDCl3) d: 0.77 (3H, t,
:
5) Ender D., Gielen H., J. Organomet. Chem., 617—618, 70—80 (2001).
6) Lappert M. F., Maskell R. K., J. Organomet. Chem., 264, 217—228
(1984).
7) Herrrmann W. A., Goosen L. J., Kocher C., Artus G. R. J., Angew.
Chem. Int. Ed. Engl., 35, 2805—2807 (1996).
8) Gade L. H., Cesar V., Bellemin-Laponaz S., Angew. Chem. Int. Ed.
Engl., 43, 1014—1017 (2004).
9) Ukai T., Tanaka R., Dokawa S., J. Pharm. Soc. Jpn., 63, 296—300
(1943).
10) Ugai T., Dokawa T., Tsubokawa S., J. Pharm. Soc. Jpn., 64, 3—4
(1944).
11) Breslow R., J. Am. Chem. Soc., 80, 3719—3726 (1958).
12) Breslow R., McNeils E., J. Am. Chem. Soc., 81, 3080—3082 (1959).
13) Miyashita A., Suzuki Y., Iwamoto K., Higashino T., Chem. Pharm.
Bull., 42, 2633—2635 (1994).
Jꢀ7.5 Hz), 1.63—1.79 (2H, m), 2.37 (3H, s), 4.16 (1H, q, Jꢀ7.5 Hz), 4.84
(1H, bs), 6.93 (2H, d, Jꢀ8.6 Hz), 7.09—7.13 (4H, m), 7.49 (2H, d,
Jꢀ8.6 Hz). 13C-NMR (CDCl3) d: 10.5, 21.6, 30.6, 59.2, 127.1, 128.1, 128.6,
129.4, 133.3, 137.5, 139.2, 143.4. MS (FAB) m/z 324 (Mꢂ1).
N-[1-(2-Chlorophenyl)propyl]-4-methylbenzenesulfonamide (3c): Color-
less needles (recrystallized from n-hexane/CH2Cl2), mp 130—132 °C; IR
(ATR) cmꢁ1 3269, 1319, 1155. 1H-NMR (CDCl3) d: 0.82 (3H, t,
:
Jꢀ7.5 Hz), 1.72—1.78 (2H, m), 2.32 (3H, s), 4.64 (1H, q, Jꢀ7.5 Hz), 5.32
(1H, d, Jꢀ7.5 Hz ), 7.03—7.15 (6H, m), 7.55 (2H, d, Jꢀ8.6 Hz). 13C-NMR
(CDCl3) d: 10.5, 21.5, 29.6, 57.0, 126.9, 127.1, 128.3, 128.5, 129.3, 129.7,
132.4, 137.2, 138.3, 143.1. FAB-MS m/z: 324.0840 (Mꢂ1) (Calcd for
C16H19NO2S: 324.0825).
N-[1-(4-Methylphenyl)propyl]-4-methylbenzenesulfonamide32) (3d): Col-
orless needles (recrystallized from n-hexane/CH2Cl2), mp 114—116 °C; IR
(ATR) cmꢁ1 3261, 1315, 1157. 1H-NMR (CDCl3) d: 0.76 (3H, t,
:
14) Miyashita A., Suzuki Y., Kobayashi M., Kuriyama N., Higashino T.,
Heterocycles, 43, 509—512 (1996).
Jꢀ7.5 Hz), 1.66—1.82 (2H, m), 2.26 (3H, s), 2.36 (3H, s), 4.12 (1H, q,
Jꢀ6.9 Hz), 4.80 (1H, d, Jꢀ6.9 Hz), 6.88 (2H, d, Jꢀ8.0 Hz), 6.95 (2H, d,
Jꢀ8.0 Hz), 7.11 (2H, d, Jꢀ8.0 Hz), 7.53 (2H, d, Jꢀ8.0 Hz). 13C-NMR
(CDCl3) d: 10.6, 21.1, 21.6, 30.6, 59.7, 126.6, 127.2, 129.1, 129.4, 131.6,
137.2, 137.7, 143.0. MS (FAB) m/z 304 (Mꢂ1).
15) Stetter H., Angew. Chem., 88, 695—704 (1976).
16) Stetter H., Kuhlmann H., Chem. Ber., 109, 2890—2896 (1976).
17) Stetter H., Kuhlmann H., Organic Reactions, 40, 407—496 (1991).
18) Grasa G. A., Kissling R. M., Nolan S. P., Org. Lett., 4, 3583—3586
(2002).
19) Nyce G. W., Lamboy J. A., Connor E. F., Waymouth R. M., Hedrick
L., Org. Lett., 4, 3587—3590 (2002).
20) Miyashita A., Obae K., Suzuki Y., Iwamoto K., Oishi E., Higashino T.,
Heterocycles, 45, 2159—2173 (1997).
21) Miyashita A., Suzuki Y., Iwamoto K., Oishi E., Higashino T., Hetero-
cycles, 49, 405—413 (1998).
22) Miyashita A., Suzuki Y., Iwamoto K., Higashino T., Chem. Pharm.
Bull., 46, 390—399 (1998).
N-[1-(2-Methoxyphenyl)propyl]-4-methylbenzenesulfonamide (3e): Col-
orless crystalline powder (recrystallized from n-hexane/CH2Cl2), mp 115—
118 °C; IR (ATR) cmꢁ1: 3273, 1317, 1155. 1H-NMR (CDCl3) d: 0.82 (3H, t,
Jꢀ7.5 Hz), 1.69—1.90 (2H, m), 2.27 (3H, s), 3.68 (3H, s), 4.18—4.24 (1H,
m), 5.57 (1H, d, Jꢀ10.3 Hz), 6.56 (1H, d, Jꢀ8.0 Hz), 6.68 (1H, t,
Jꢀ7.5 Hz), 6.80 (1H, dd, Jꢀ7.5, 1.7 Hz), 6.96 (2H, d, Jꢀ8.6 Hz), 7.05
(1H, ddd, Jꢀ8.0, 7.5, 1.7 Hz), 7.42 (2H, d, Jꢀ8.6 Hz). 13C-NMR (CDCl3)
d: 11.2, 21.5, 29.0, 55.1, 59.4, 110.6, 120.5, 126.9, 127.9, 128.4, 128.9,
129.4, 129.8, 137.7, 142.5. FAB-MS m/z: 320.1304 (Mꢂ1) (Calcd for
C17H22NO3S: 320.1320).
N-Benzyl-4-methylbenzenesulfonamide36) (4a): Colorless crystalline pow-
der (recrystallized from n-hexane/CH2Cl2), mp 108—110 °C; IR (ATR)
cmꢁ1: 3267, 1321, 1159. 1H-NMR (CDCl3) d: 2.44 (3H, s), 4.12 (2H, d,
Jꢀ6.3 Hz), 4.61 (1H, t, Jꢀ6.3 Hz), 7.19 (2H, d, Jꢀ8.6 Hz), 7.26—7.32 (5H,
m), 7.76 (2H, d, Jꢀ8.6 Hz). 13C-NMR (CDCl3) d: 21.6, 47.4, 127.3, 128.0,
128.1, 128.8, 129.9, 136.3, 136.9, 143.7. MS (FAB) m/z 262 (Mꢂ1).
(S)-3-(1-Pivaloylpyrrolidin-2-ylmethyl)-1-(2,4,6-trimethylphenyl)imi-
dazolium Chloride 6 Triethylamine (2.8 ml, 20 mmmol) was added to a
solution of (S)-2-(chloromethyl)pyrrolidine hydrochloride (10 mmol) in
dichloromethane (20 ml) at 0 °C, and subsequently, pivaloyl chloride
(1.23 ml, 10 mmol) was added dropwise. The mixture was stirred overnight
at room temperature, and then dichloromethane was removed under reduced
pressure. The residue was extracted with diethyl ether, washed with 2 N HCl,
and dried over MgSO4. The solvent was removed to afford crude (S)-2-
(chloromethyl)-1-pivaloylpyrrolidine (1.28 g, 63%) as a brown oil, to which
chlorobenzene (20 ml) and 1-mesitylimidazole (1.18 g, 6.33 mmol) were
added and the mixture was refluxed for 3 d. After the mixture was cooled,
the resultant precipitates were collected by filtration to afford imidazolium
23) Suzuki Y., MD. A. B., Muramatsu K., Sato M., Tetrahedron, 62,
4227—4231 (2006).
24) Song J. J., Gallou F., Reeves J. T., Tan Z., Yee N. K., Senanayake C. H.,
J. Org. Chem., 71, 1273—1276 (2006).
25) Fukuda Y., Maeda Y., Ishii S., Kondo K., Aoyama T., Synthesis, 4,
589—590 (2006).
26) Kano T., Sasaki K., Konishi T., Mii H., Maruoka K., Tetrahedron Lett.,
47, 4615—4618 (2006).
27) Fraser P. K., Woodward S., Tetrahedron Lett., 42, 2747—2749 (2001).
28) Guillen F., Winn C. L., Alexakis A., Tetrahedron: Asymmetry, 12,
2083—2086 (2001).
29) Pytkowicz J., Roland S., Mangeney P., Tetrahedron: Asymmetry, 12,
2087—2089 (2001).
30) Lee K. Y., Lee C. G., Kim J. N., Tetrahedron Lett., 44, 1231—1234
(2003).
31) Alexakis A., Benhaim C., Rosset S., Human M., J. Am. Chem. Soc.,
124, 5262—5263 (2002).
32) Soeta T., Nagai K., Fujihara H., Kuriyama M., Tomioka K., J. Org.
Chem., 68, 9723—9727 (2003).
33) Wang M.-C., Xu C.-L., Zou Y.-X., Liu H.-M., Wang D.-K., Tetrahe-
dron Lett., 46, 5413—5416 (2005).
34) Herrrmann W. A., Goossen L. J., Kocher C., Artus G. R. J., Angew.
Chem. Int. Ed. Engl., 35, 2805—2807 (1996).
35) Nijhuis W. H. N., Verboom W., El-Fadl A. A., Van Hummel G. J.,
Reinhoudt D. N., J. Org. Chem., 54, 209—216 (1989).
36) Gao F., Deng M., Qiam C., Tetrahedron, 61, 12238—12243 (2005).
salt 6 as pale brown scales (1.05 g, 46%). mp 277—278 °C; IR (ATR) cmꢁ1
:
1
1604. H-NMR (CDCl3) d: 1.24 (9H, s, t-Bu), 1.84—1.92 (1H, m), 1.94—
2.22 (1H, m), 2.08 (6H, s, o-CH3), 2.14—2.20 (1H, m), 2.34 (3H, p-CH3),
2.37—2.47 (1H, m), 3.68 (1H, dt, Jꢀ10.3, 7.4 Hz), 3.82 (1H, ddd, Jꢀ10.3,
8.0, 4.6 Hz), 4.46—4.50 (1H, m), 4.71 (1H, dd, Jꢀ13.2, 4.0 Hz), 5.10 (1H,
dd, Jꢀ13.2, 7.4 Hz), 7.00 (2H, s), 7.07 (1H, t, Jꢀ1.7 Hz), 7.80 (1, t,
Jꢀ1.7 Hz), 10.9 (1H, s). 13C-NMR (CDCl3) d: 17.7, 17.8, 21.2, 25.3, 26.9,
27.6, 39.3, 48.4, 51.5, 59.7, 122.8, 123.0, 130.0, 130.8, 134.2, 134.2, 139.3,
139.3, 141.4, 178.0. FAB-MS m/z: 354.2559 (Calcd for C22H22N3O: